Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Advances in the pathogenesis and treatment of IBD.

Braus NA, Elliott DE.

Clin Immunol. 2009 Jul;132(1):1-9. doi: 10.1016/j.clim.2009.02.006. Epub 2009 Mar 24. Review.

2.

Biologic therapy for inflammatory bowel disease.

Ardizzone S, Bianchi Porro G.

Drugs. 2005;65(16):2253-86. Review.

PMID:
16266194
3.

Immunomodulator therapy in inflammatory bowel disease.

Choi PM, Targan SR.

Dig Dis Sci. 1994 Sep;39(9):1885-92. Review.

PMID:
7521821
4.

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.

Dig Liver Dis. 2005 Jun;37(6):407-17. Review.

PMID:
15893279
5.

[Immunopathogenesis of inflammatory bowel diseases].

Neurath MF, Schürmann G.

Chirurg. 2000 Jan;71(1):30-40. Review. German.

PMID:
10662999
6.

Immune aspects of the pathogenesis of inflammatory bowel disease.

Hisamatsu T, Kanai T, Mikami Y, Yoneno K, Matsuoka K, Hibi T.

Pharmacol Ther. 2013 Mar;137(3):283-97. doi: 10.1016/j.pharmthera.2012.10.008. Epub 2012 Oct 26. Review.

PMID:
23103332
7.

Immunosuppressive therapies for inflammatory bowel disease.

Zenlea T, Peppercorn MA.

World J Gastroenterol. 2014 Mar 28;20(12):3146-52. doi: 10.3748/wjg.v20.i12.3146. Review.

8.

Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.

Ghosh N, Chaki R, Mandal V, Lin GD, Mandal SC.

Int Rev Immunol. 2010;29(1):4-37. doi: 10.3109/08830180903437212. Review.

PMID:
20100080
9.

Inflammatory bowel disease: pathogenesis.

Zhang YZ, Li YY.

World J Gastroenterol. 2014 Jan 7;20(1):91-9. doi: 10.3748/wjg.v20.i1.91. Review.

10.

Refractory IBD: medical management.

Tremaine WJ.

Neth J Med. 1997 Feb;50(2):S12-4. Review.

PMID:
9050327
11.

Immune dysfunction in inflammatory bowel disease.

Neuman MG.

Transl Res. 2007 Apr;149(4):173-86. Review.

PMID:
17383591
12.

Recent understanding of IBD pathogenesis: implications for future therapies.

Kucharzik T, Maaser C, Lügering A, Kagnoff M, Mayer L, Targan S, Domschke W.

Inflamm Bowel Dis. 2006 Nov;12(11):1068-83. Review.

PMID:
17075348
13.

CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.

Vuckovic S, Florin TH, Khalil D, Zhang MF, Patel K, Hamilton I, Hart DN.

Am J Gastroenterol. 2001 Oct;96(10):2946-56.

PMID:
11693331
14.

Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality?

van Hogezand RA, Verspaget HW.

Neth J Med. 1996 Feb;48(2):64-7. Review.

PMID:
8819802
15.

Immunosuppressive drugs in the treatment of inflammatory bowel disease.

Aranda R, Horgan K.

Semin Gastrointest Dis. 1998 Jan;9(1):2-9. Review.

PMID:
9547850
16.

Biologic targeting in the treatment of inflammatory bowel diseases.

Bosani M, Ardizzone S, Porro GB.

Biologics. 2009;3:77-97. Epub 2009 Jul 13. Retraction in: Biologics. 2014;8:39.

18.

Etiology and pathogenesis of inflammatory bowel disease.

Schmidt C, Stallmach A.

Minerva Gastroenterol Dietol. 2005 Jun;51(2):127-45. Review.

PMID:
15990703
19.

Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.

Satsangi J, Welsh KI, Bunce M, Julier C, Farrant JM, Bell JI, Jewell DP.

Lancet. 1996 May 4;347(9010):1212-7.

PMID:
8622450

Supplemental Content

Support Center